An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers
- 1 December 2010
- Vol. 29 (2) , 266-273
- https://doi.org/10.1016/j.vaccine.2010.10.038
Abstract
No abstract availableKeywords
Funding Information
- Influenza Centre, University of Bergen
- Bergen Clinical Vaccine Consortium (BCVC) Innovest
- Haukeland University Hospital
- Norwegian Directorate of Health
- Ministry of Health and Care Services
This publication has 22 references indexed in Scilit:
- Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus InfectionNew England Journal of Medicine, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human populationProceedings of the National Academy of Sciences, 2009
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Reproducibility of Serologic Assays for Influenza Virus A (H5N1)Emerging Infectious Diseases, 2009
- Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccineProceedings of the National Academy of Sciences, 2009
- A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccineVaccine, 2009
- Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical TrialThe Journal of Infectious Diseases, 2008
- Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza VaccinePLOS ONE, 2008